Accreditation Valid Until 03/03/2025
Please also watch Small Molecules (JAKi/S1P agonists), IL-12/23 and IL-23 Receptor Antagonists, What is New in Anti -TNFs and Anti-Integrins?, and the IBD Immunology and Emerging Therapies Q & A.
IBD Immunology and Emerging Therapies: Where Are We and Where We Are Going
Media formats available:
Details
Presenters
Comments
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Discuss studies to identify next generation IBD therapies
- Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
- Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
- Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
- Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
- Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators
Target Audience
This activity is designed for physicians and nurses to give updates and updated approaches to treatment of patients with inflammatory bowel diseases. This activity may also be of interest to nutritionists or anyone who specializes in gastroenterology, internal medicine, or surgery.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by the Crohn’s & Colitis Foundation and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.Disclosure of Conflicts of Interest
Planning Committee and Disclosures:
All relevant financial relationships have been mitigatedMatthew Ciorba, MD
Research Support/Grants – Janssen Pharmaceuticals
Consulting / Executive Role / Advisory Committee – Bristol-Myers Squibb Co/BMS, Janssen Scientific Affairs LLC, Takeda Pharmaceuticals Company Ltd
Authorship (e.g. book royalties or publication agreements) – Pfizer, Inc.Parakkal Deepak, MBBS, MS
Research Support/Grants – Alimentiv Inc, Arena Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Co/BMS, Celgene Corporation, CorEvitas LLC, PredictImmune
Consulting / Executive Role / Advisory Committee – AbbVie Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Co/BMS, SCIPHER, South Asian IBD AllianceSara Horst, MD, MPH
Consulting / Executive Role / Advisory Committee – AbbVie Inc, Gilead Sciences, Janssen, Takeda PharmaceuticalsDan Schneiderjohn, MPH
No financial relationships to discloseJoanna Davidson Gilbertsen, RN, BSN
No financial relationships to discloseIndependent Reviewer:
Kemmian D. Johnson, MD, MPH
No financial relationships to discloseDisclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Edward L. Barnes, MD, MPH
Katie Dunleavy, MB, BCh, BAO
David A. Schwartz, MD
Ira Leeds, MD, FACS, FASCRS
